FIELD: biotechnology.
SUBSTANCE: monoclonal antibody or its antigen-binding fragment, which specifically bind human tau-protein, its production and use are proposed. The antibody contains HCDR1 according to SEQ ID NO: 732, HCDR2 according to SEQ ID NO: 734, HCDR3 according to SEQ ID NO: 736, and LCDR1 according to SEQ ID NO: 846, LCDR2 according to SEQ ID NO: 848, LCDR3 according to SEQ ID NO: 850, as defined according to Kabat method. Alternatively, a heavy chain contains HCDR1 according to SEQ ID NO: 1002, HCDR2 according to SEQ ID NO: 1004, and HCDR3 according to SEQ ID NO: 1006, and a light chain contains LCDR1 according to SEQ ID NO: 1116, LCDR2 according to SEQ ID NO: 1118, and LCDR3 according to SEQ ID NO: 1120.
EFFECT: antibody or its antigen-binding fragment are used for reduction in levels of sarkosyl-insoluble tau-protein in a subject and in the treatment of tauopathy.
40 cl, 33 dwg, 15 tbl, 19 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODY CAPABLE OF BINDING TO THYMIC STROMAL LYMPHOPOIETIN, AND USE THEREOF | 2020 |
|
RU2825304C2 |
| T- CELLS WITH COSTIMULATING CHIMERIC ANTIGEN RECEPTOR TARGETING IL13Rα2 | 2015 |
|
RU2749922C2 |
| CONNECTIVE TISSUE GROWTH FACTOR ANTIBODY AND USE THEREOF | 2020 |
|
RU2819228C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING ANTI-IL-5 ANTIBODY, AND USE THEREOF | 2020 |
|
RU2824390C2 |
| ANTIBODY TO PD-1, ITS ANTIGEN-BINDING FRAGMENT AND ITS PHARMACEUTICAL USE | 2020 |
|
RU2807484C2 |
| BISPECIFIC PROTEIN | 2019 |
|
RU2784486C1 |
| ANTIBODIES THAT BIND TUMOR TISSUE FOR DIAGNOSIS AND TREATMENT | 2020 |
|
RU2806915C2 |
| ANTIBODY TO CD3 AND ITS PHARMACEUTICAL USE | 2019 |
|
RU2802272C2 |
| COMPOSITIONS AND METHODS FOR SELECTIVE PROTEIN EXPRESSION | 2017 |
|
RU2795467C2 |
| SOLUBILIZED APIRASES, METHODS AND APPLICATIONS | 2019 |
|
RU2791992C2 |
